[{"id":"4893e4f0-4406-4533-aee9-63908fb17f49","acronym":"FINESTdm","url":"https://clinicaltrials.gov/study/NCT04681820","created_at":"2021-01-19T20:46:48.858Z","updated_at":"2024-07-02T16:35:41.428Z","phase":"","brief_title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","source_id_and_acronym":"NCT04681820 - FINESTdm","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-01"}]